SCHEMBL6317624

SCHEMBL6317624

COc1ccc(CNC(=O)c2c(-c3ccc(C)o3)noc2N)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.59
MAPT P10636 5/20 0.52
ALDH1A1 P00352 5/20 0.52
L3MBTL1 Q9Y468 1/20 0.49
TSHR P16473 1/20 0.47
RAB9A P51151 2/20 0.47
ATM Q13315 1/20 0.47
POLB P06746 2/20 0.46
MMP3 P08254 2/20 0.46
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
ESR1 P03372 1/20 0.45
KMT2A Q03164 1/20 0.45
MMP2 P08253 2/20 0.45
MMP1 P03956 1/20 0.45
APAF1 O14727 1/20 0.45
HTT P42858 1/20 0.45
NLRP3 Q96P20 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316789 0.90 SMN1; SMN2 (0.53) HPGDMAPTPOLBLMNASMN1; SMN2
SCHEMBL6322602 0.89 KMT2A (0.49) HPGDMAPTALDH1A1ATMPOLB
SCHEMBL6315026 0.89 MAPT (0.53) HPGDMAPTALDH1A1L3MBTL1TSHR
SCHEMBL6321626 0.88 ADRB2 (0.47) HPGDMAPTALDH1A1SMN1; SMN2
SCHEMBL6317800 0.87 GAA (0.53) HPGDMAPTALDH1A1TSHRLMNA
SCHEMBL6318079 0.87 L3MBTL1 (0.48) HPGDALDH1A1L3MBTL1LMNASMN1; SMN2
SCHEMBL6324493 0.85 ADORA2A (0.49) HPGDMAPTALDH1A1TSHRLMNA
SCHEMBL6317613 0.84 LSS (0.42) HPGDMAPTATMSMN1; SMN2KMT2A
SCHEMBL6315718 0.83 ALDH1A1 (0.64) HPGDMAPTALDH1A1L3MBTL1TSHR
SCHEMBL6316430 0.82 S1PR3 (0.43) HPGDALDH1A1TSHRATMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 HPGD 2923/4885MAPT 281/4885ALDH1A1 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.